Eli Lilly (LLY)
$144.90 1.52 (1.06%)
19:57 EST LLY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 157.28B
PE Ratio 135.42
Volume (Avg. Vol.) 4.13M
Day's Range 143.11 - 145.64
52-Week Range 115.92 - 170.75
Dividend & Yield 2.25 (1.55%)
LLY Stock Predictions, Articles, and Eli Lilly News
- From InvestorPlace
- From the Web
By Joel Baglole
Investors are banking on an upsurge in pharmaceutical stocks once various vaccines and other therapies gain commercial approval from the U.S. Food and Drug Administration (FDA). Here is a list of pharmaceutical companies that stand to benefit in the coming months.
Investors have these seven election stocks to consider avoiding, as uncertainties grow in the near-term and market selling rises.
By Ian Cooper
While airlines are still plenty of volatility, I’d use the weakness to pick up "blood in the street" opportunities like JBLU stock.
Eli Lilly stock is climbing slightly higher Wednesday after it became the first company to release antibody drug results.
The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.
LLY stock has been the best large-cap pharma play in recent years. With a strong pipeline and reasonable valuation, that should continue.
Some folks consider LLY stock a dull investment, but don't forget that Eli Lilly could play a pivotal role in the battle against Covid-19.
There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure.
Eli Lilly (LLY) is in the news Tuesday after a successful breast cancer drug trial sent LLY stock higher on interim results.
Eli Lilly is known for its Big Pharma dominance, but it's also leading cutting-edge coronavirus research. That makes LLY stock a buy here.
Friday's big stock charts feature pharmaceutical-market names that recently posted terrific earnings data.
Healthcare stocks are pulling the market higher today. Here are three of the best stocks to buy in the sector right now.
While many stocks have suffered during the coronavirus crisis, some have thrived. Here are three winners that are the best stocks to buy.
Eli Lilly, Domino's Pizza, Gilead Sciences, Las Vegas Sands and Inovio Pharmaceuticals were our top stock trades for Friday.
Despite a year-to date drop of -13.9%, the S&P 500 could still be overpriced by 35%. If the S&P 500 is overvalued, component stocks must be.
By Thomas Niel
With its coronavirus catalyst pushing shares higher, now is not the time to chase this "too hot to touch" name. Instead, consider pharma names selling at lower valuations than LLY stock. These may offer similar potential for gains, and at more reasonable valuations.
Roku shares fall as its CFO resigns. Here's what else happened in the stock market today, as bulls search for new highs.
From Yahoo Finance
(Bloomberg) -- Vir Biotechnology Inc.’s stock has lost some of its luster after quadrupling earlier this year as competition heats up for Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 115% leap this year. Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend. Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak,” Scangos said in an interview. An interim look at late-stage data for VIR-7831 is expected in January.Regeneron has touted its two-antibody cocktail as being better than single-antibody treatments like those from Lilly or Vir. Yet Scangos, a former Biogen Inc. chieftain, said that while Lilly and Regeneron’s medicines block the ability of the virus to infect cells, the virus could evade these antibodies by mutating.‘Babe Ruth’“Would you rather have two random baseball players or Babe Ruth?,” he said. “It’s not just the number but the quality and the characteristics of the antibody.”Vir’s antibody was developed not from a Covid-19 patient but from one who’d recovered from severe acute respiratory syndrome, or SARS, which is also caused by a coronavirus. The company chose an antibody that also works against Covid-19 and Scangos postulates that it responds to something in the SARS and Covid viruses that hasn’t changed over years of viral evolution.He also sees potential advantage for Vir’s antibody in its engagement of part of the immune system where Lilly and Regeneron’s molecules have had less potent activity.Baird’s Madhu Kumar, the only analyst with a sell-equivalent rating on Vir, is skeptical. He said this particular component of Lilly and Regeneron’s antibodies may be what led to some safety signals and “could trigger inflammatory cascades that could be detrimental to patients.” This particularly concerns hospitalized patients, which Vir is still studying, Kumar told Bloomberg.Email requests for comment to Lilly and Regeneron weren’t returned.Much of Kumar’s skepticism is tied to Vir’s valuation. Even after the stock pulled way back from a Feb. 27 record, it’s still has more than doubled this year. He’s also wary of the market for antibodies in general because successful vaccine results from Pfizer Inc. and partner BioNTech SE as well as Moderna Inc. have blunted its longer term “tail value.”Outside of Covid-19, Kumar has a positive view on Vir. “There’s a real company behind this,” he said, calling out Vir’s hepatitis B RNAi platform. Vir’s stock slipped as much as 3.2% in early Tuesday trading.Others on Wall Street take a more optimistic view with five analysts deeming it a buy, and one with a hold rating. The average analyst price target of $55 suggests the Street expects shares may almost double over the next 12 months.GlaxoSmithKline Plc is also a believer and has invested $250 million in San Francisco-based Vir. The duo are in a deal to pursue not only Covid-19 but future coronaviruses using CRISPR screening technology and artificial intelligence to find new compounds.(Updates to add shares in eleventh paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Navellier RatingsPowered by Portfolio Grader